EMA Authorised: Ruxience (rituximab) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Ruxience, a rituximab biosimilar by Pfizer Europe MA EEIG, for several indications including chronic lymphocytic leukemia, rheumatoid arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Microscopic Polyangiitis
• Pemphigus
• Rheumatoid Arthritis

Drugs mentioned

• RUXIENCE (RITUXIMAB-PVVR)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid;Microscopic Polyangiitis;Pemphigus. MAH: Pfizer Europe MA EEIG. Decision date: 11/07/2025